Ipsen S.A
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more
Ipsen S.A (IPSEF) - Total Liabilities
Latest total liabilities as of June 2025: $2.60 Billion USD
Based on the latest financial reports, Ipsen S.A (IPSEF) has total liabilities worth $2.60 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ipsen S.A - Total Liabilities Trend (2004–2024)
This chart illustrates how Ipsen S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ipsen S.A Competitors by Total Liabilities
The table below lists competitors of Ipsen S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fujian Anjoy Foods Co Ltd
SHG:603345
|
China | CN¥4.88 Billion |
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
USA | $5.14 Million |
|
Meinian Onehealth Healthcare Holdings Co Ltd
SHE:002044
|
China | CN¥10.84 Billion |
|
Rayonier Inc
NYSE:RYN
|
USA | $1.20 Billion |
|
Pennon Group Plc
PINK:PEGRF
|
USA | $6.02 Billion |
|
Eutelsat Group
LSE:ETL
|
UK | €4.34 Billion |
|
Western Union Co
NYSE:WU
|
USA | $6.86 Billion |
|
Hangzhou Great Star Industrial Co Ltd
SHE:002444
|
China | CN¥4.02 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Ipsen S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ipsen S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ipsen S.A (2004–2024)
The table below shows the annual total liabilities of Ipsen S.A from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.26 Billion | -9.68% |
| 2023-12-31 | $2.50 Billion | +10.03% |
| 2022-12-31 | $2.27 Billion | +0.82% |
| 2021-12-31 | $2.25 Billion | +2.61% |
| 2020-12-31 | $2.20 Billion | -14.04% |
| 2019-12-31 | $2.55 Billion | +66.49% |
| 2018-12-31 | $1.53 Billion | -0.14% |
| 2017-12-31 | $1.54 Billion | +44.74% |
| 2016-12-31 | $1.06 Billion | +48.98% |
| 2015-12-31 | $712.40 Million | +10.38% |
| 2014-12-31 | $645.40 Million | +9.10% |
| 2013-12-31 | $591.59 Million | -6.81% |
| 2012-12-31 | $634.84 Million | +2.73% |
| 2011-12-31 | $617.97 Million | +3.17% |
| 2010-12-31 | $598.96 Million | +1.09% |
| 2009-12-31 | $592.52 Million | -15.52% |
| 2008-12-31 | $701.36 Million | +34.41% |
| 2007-12-31 | $521.81 Million | +7.29% |
| 2006-12-31 | $486.37 Million | +51.32% |
| 2005-12-31 | $321.41 Million | -23.83% |
| 2004-12-31 | $421.98 Million | -- |